STOCK PURCHASE AGREEMENT by and among IBIS BIOSCIENCES, INC., ISIS PHARMACEUTICALS, INC. and ABBOTT MOLECULAR INC. Dated: December 17, 2008Stock Purchase Agreement • February 26th, 2009 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of the 17th day of December, 2008, by and among Isis Pharmaceuticals, Inc., a Delaware corporation (“Isis”), Ibis Biosciences, Inc., a Delaware corporation and Affiliate of Isis (“Ibis”), and Abbott Molecular Inc., a Delaware corporation (“AMI”) and Affiliate of Abbott Laboratories, an Illinois corporation (“Abbott”). AMI, Ibis and Isis are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
LOAN AGREEMENTLoan Agreement • February 26th, 2009 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
THIS LOAN AGREEMENT dated as of October 15, 2008 between ISIS PHARMACEUTICALS, INC., a Delaware Corporation (together with its successors and permitted assigns, “Borrower”), and RBS ASSET FINANCE, INC., a New York corporation (together with its successors and assigns, “Lender”).
REGULUS THERAPEUTICS LLC EMPLOYMENT AGREEMENTEmployment Agreement • February 26th, 2009 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • California
This EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into effective as of December 29, 2008 by and between Regulus Therapeutics LLC, a Delaware limited liability corporation (the “Company”), and Kleanthis G. Xanthopoulos, Ph.D. (the “Executive”). The Company and the Executive are hereinafter collectively referred to as the “Parties”, and individually referred to as a “Party”.
PRE-CLINICAL DEVELOPMENT COLLABORATION AGREEMENTPre-Clinical Development Collaboration Agreement • February 26th, 2009 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • England
This Pre-Clinical Development Collaboration Agreement (this “Agreement”) is entered into effective as of March 23, 2007 (the “Effective Date”) by and between Isis Pharmaceuticals, Inc., a Delaware corporation (“Isis”) and Korea Institute of Toxicology, a Korean government-established institute for non-clinical research (“KIT”).
